CD40 Agonist and PD-1 Inhibitor in HNSCC

计划入组 27 人 · 首次发布于 2023 年 12 月 7 日

Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure

计划入组 60 人 · 首次发布于 2025 年 7 月 31 日

Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis

计划入组 34 人 · 首次发布于 2025 年 2 月 5 日

PD-1/LAG-3 bispecific mAbs

PD-L1 x ABCB1

PD-RX Pharmaceuticals, Inc.

United States

NHI-1

United States

Xi'an No.1 Hospital

China

InduPro Therapeutics Secures Strategic Investment from Sanofi for Novel Bispecific PD-1 Agonist Program

FDA Grants Fast Track Designation to OncoC4's PD-1/VEGF Bispecific Cesalatamig for PD-(L)1-Refractory NSCLC

Researchers Identify Anti-Mouse PD-1 Agonist Antibodies That Inhibit T Cell Activation